|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Test Statisticsa,b** | | | | | | | | | | | | | | | | | | | | |
|  | **CXCR5** | **TFH** | **TFR** | **RATIO** | **TREG** | **PD1CXCR5** | **PD1ONCXCR5** | **ICOSCXCR5** | **ICOSONCXCR5** | **STAT3CXCR5** | **STAT3ONCXCR5** | **STAT4CXCR5** | **STAT4ONCXCR5** | **STAT5CXCR5** | **STAT5ONCXCR5** | **IL21CXCR5** | **IL21ONCXCR5** | **CXCL13** | **TGFB** |
| **Chi-Square** | **.931** | **.851** | **.537** | **.045** | **.942** | **.637** | **.314** | **.441** | **1.797** | **1.753** | **3.316** | **2.088** | **1.874** | **.033** | **1.966** | **1.852** | **1.430** | **1.772** | **.535** |
| **df** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** |
| **Asymp. Sig.** | **.628** | **.653** | **.765** | **.978** | **.624** | **.727** | **.855** | **.802** | **.407** | **.416** | **.191** | **.352** | **.392** | **.984** | **.374** | **.396** | **.489** | **.412** | **.765** |
| **a. Kruskal Wallis Test** | | | | | | | | | | | | | | | | | | | | |
| **b. Grouping Variable: subCAD** | | | | | | | | | | | | | | | | | | | | |

**Table S4. Kruskal-Wallis H analysis of immune parameters between three groups of recipients with CAD divided by eGFR.**

34 patients with CAD (eGFR<60 ml/min/1.73m2) were divided into three groups: Group 1 with eGFR from 30 to 60 ml/min/1.73m2 (N=19); Group 2 with eGFR from 15 to 30 ml/min/1.73m2 (N=12); Group 3 with eGFR less than 15 ml/min/1.73m2 (N=3).